Literature DB >> 26397057

Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function.

Liwei Ma1, Ye Xu2, Jing Su1, Huimei Yu1, Jinsong Kang1, Hongyan Li1, Xiaoning Li1, Qi Xie1, Chunyan Yu3, Liankun Sun1, Yang Li1.   

Abstract

Lysosomes are involved in promoting resistance of cancer cells to chemotherapeutic agents. However, the mechanisms underlying lysosomal influence of cisplatin resistance in ovarian cancer remain incompletely understood. We report that, compared with cisplatin-sensitive SKOV3 cells, autophagy increases in cisplatin-resistant SKOV3/DDP cells treated with cisplatin. Inhibition of early-stage autophagy enhanced cisplatin-mediated cytotoxicity in SKOV3/DDP cells, but autophagy inhibition at a later stage by disturbing autophagosome-lysosome fusion is more effective. Notably, SKOV3/DDP cells contained more lysosomes than cisplatin-sensitive SKOV3 cells. Abundant lysosomes and lysosomal cathepsin D activity were required for continued autolysosomal degradation and maintenance of autophagic flux in SKOV3/DDP cells. Furthermore, SKOV3/DDP cells contain abundant lysosomal ATP required for lysosomal function, and inhibition of lysosomal ATP accumulation impaired lysosomal function and blocked autophagic flux. Therefore, our findings suggest that lysosomes at least partially contribute to cisplatin resistance in ovarian cancer cells through their role in cisplatin-induced autophagic processes, and provide insight into the mechanism of cisplatin resistance in tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397057     DOI: 10.3892/ijo.2015.3176

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.

Authors:  Dobrina Tsvetkova; Stefka Ivanova
Journal:  Molecules       Date:  2022-04-11       Impact factor: 4.927

Review 2.  The Function of V-ATPases in Cancer.

Authors:  Laura Stransky; Kristina Cotter; Michael Forgac
Journal:  Physiol Rev       Date:  2016-07       Impact factor: 37.312

3.  Protective effect of autophagy in neural ischemia and hypoxia: Negative regulation of the Wnt/β-catenin pathway.

Authors:  Zhen-Yu Shi; Jie-Xin Deng; Su Fu; Lai Wang; Qiang Wang; Bin Liu; Yong-Qiang Li; Jin-Bo Deng
Journal:  Int J Mol Med       Date:  2017-09-28       Impact factor: 4.101

4.  p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.

Authors:  Xiao-Yu Yan; Yu Zhang; Juan-Juan Zhang; Li-Chao Zhang; Ya-Nan Liu; Yao Wu; Ya-Nan Xue; Sheng-Yao Lu; Jing Su; Lian-Kun Sun
Journal:  Cancer Sci       Date:  2017-06-25       Impact factor: 6.716

5.  Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells.

Authors:  Miguel Angel Merlos Rodrigo; Hana Buchtelova; Ana Maria Jimenez Jimenez; Pavlina Adam; Petr Babula; Zbynek Heger; Vojtech Adam
Journal:  Cells       Date:  2019-03-12       Impact factor: 6.600

Review 6.  Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer.

Authors:  Xiao-Yu Yan; Xian-Zhi Qu; Long Xu; Si-Hang Yu; Rui Tian; Xin-Ru Zhong; Lian-Kun Sun; Jing Su
Journal:  Cancer Cell Int       Date:  2020-04-16       Impact factor: 5.722

Review 7.  Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.

Authors:  Mohamed Haider; Amr Elsherbeny; Valeria Pittalà; Valeria Consoli; Maha Ali Alghamdi; Zahid Hussain; Ghalia Khoder; Khaled Greish
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

8.  ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.

Authors:  Yunjie Xu; Weinan Gao; Yong Zhang; Shanshan Wu; Yanan Liu; Xinyue Deng; Lili Xie; Jiayan Yang; Huimei Yu; Jing Su; Liankun Sun
Journal:  Int J Oncol       Date:  2018-07-09       Impact factor: 5.650

Review 9.  The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

Authors:  Jiabei Zhou; Yu Kang; Lu Chen; Hua Wang; Junqing Liu; Su Zeng; Lushan Yu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.